2020
DOI: 10.3390/jof6040275
|View full text |Cite
|
Sign up to set email alerts
|

Coronavirus Disease 2019 (COVID-19) in a Patient with Disseminated Histoplasmosis and HIV—A Case Report from Argentina and Literature Review

Abstract: The disease caused by the new SARS-CoV-2, known as Coronavirus disease 2019 (COVID-19), was first identified in China in December 2019 and rapidly spread around the world. Coinfections with fungal pathogens in patients with COVID-19 add challenges to patient care. We conducted a literature review on fungal coinfections in patients with COVID-19. We describe a report of a patient with disseminated histoplasmosis who was likely infected with SARS-CoV-2 and experienced COVID-19 during hospital care in Buenos Aire… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
50
0
4

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 46 publications
(54 citation statements)
references
References 58 publications
0
50
0
4
Order By: Relevance
“…Because SARS-CoV-2 and treatments such as dexamethasone or tocilizumab can impair the immune system, some researchers anticipated the possibility of fungal superinfection among COVID-19 patients ( 3 – 6 ). As of August 2020, researchers have documented COVID-19–associated pulmonary aspergillosis (CAPA) ( 7 9 ), invasive candidiasis ( 10 ), coccidioidomycosis ( 11 ), fusariosis ( 12 ), histoplasmosis ( 13 ), mucormycosis ( 14 ), pneumocystosis ( 15 ), and saccharomycosis ( 16 ). Varying cumulative rates of CAPA have been described, including rates of 0.7%–7.7% among COVID-19 patients ( 17 , 18 ), 2.5%–39.1% among ICU patients with COVID-19 ( 19 , 20 ), and 3.2%–29.6% among COVID-19 patients on mechanical ventilation ( 7 , 17 ).…”
mentioning
confidence: 99%
“…Because SARS-CoV-2 and treatments such as dexamethasone or tocilizumab can impair the immune system, some researchers anticipated the possibility of fungal superinfection among COVID-19 patients ( 3 – 6 ). As of August 2020, researchers have documented COVID-19–associated pulmonary aspergillosis (CAPA) ( 7 9 ), invasive candidiasis ( 10 ), coccidioidomycosis ( 11 ), fusariosis ( 12 ), histoplasmosis ( 13 ), mucormycosis ( 14 ), pneumocystosis ( 15 ), and saccharomycosis ( 16 ). Varying cumulative rates of CAPA have been described, including rates of 0.7%–7.7% among COVID-19 patients ( 17 , 18 ), 2.5%–39.1% among ICU patients with COVID-19 ( 19 , 20 ), and 3.2%–29.6% among COVID-19 patients on mechanical ventilation ( 7 , 17 ).…”
mentioning
confidence: 99%
“…Respecto a las histoplasmosis, uno de los casos fue diagnosticado por visualización de levaduras de Histoplasma capsulatum (Hc) en el examen directo con tinción de Giemsa del esputo y además presentó el antígeno urinario de galactomanano de histoplasma positivo (IMMY®) (21). El otro caso fue diagnosticado por detección de anticuerpos de Histoplasma capsulatum (contrainmunoelectroforesis) y además tuvo PCR específica positiva en sangre (PCR anidada: gen HcP 100 de Hc que codifica una proteína implicada en la infección y supervivencia de Hc) (17), también tuvo antígeno urinario positivo.…”
Section: Resultsunclassified
“…En los casos de criptococosis e histoplasmosis se emplearon las metodologías habituales de la Unidad Micología del Hospital F. J. Muñiz (17,19,20,21).…”
Section: Diagnósticounclassified
“…(Jehangir et al 2015 ). In light of current pandemic, it is important to emphasize that two cases of histoplasmosis co-infection on immunocompromised AIDS patients with COVID-19 have been reported recently (Messina et al 2020 ; Basso et al 2020 ).…”
Section: Bat (Guano) Mycobiotamentioning
confidence: 99%